

CLAIM AMENDMENTS

1. (Currently Amended) A composition comprising a T lymphocyte having (i) a recombinant chimeric receptor, ~~or a recombinant T-cell receptor, either of~~ which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell, ~~which cell~~ that is allogeneic to the T lymphocyte.
2. (Cancelled)
3. (Cancelled)
4. (Previously Presented) The composition of claim 1, wherein the tumor antigen is an ovarian tumor antigen.
5. (Cancelled)
6. (Cancelled)
7. (Previously Presented) The composition of claim 1, wherein the chimeric receptor comprises a single chain Fv receptor.
8. (Previously Presented) The composition of claim 1, wherein the cell is a peripheral blood mononuclear cell.
9. (Cancelled)
10. (Previously Presented) The composition of claim 4, wherein the recombinant chimeric receptor is Mov- γ .
11. (Currently Amended) A lymphocyte having a T-cell receptor reactive with a cell, ~~which cell~~ that is allogeneic to the lymphocyte, and a chimeric receptor reactive with a tumor antigen.
- 12.-39. (Cancelled)

40. (Currently Amended) A pharmaceutical composition comprising:
a T lymphocyte containing a recombinant chimeric receptor reactive with a tumor antigen and an endogenous T-cell receptor reactive with a cell, ~~which cell~~ that is allogeneic to the T lymphocyte; and
a pharmaceutically acceptable carrier.
41. (Currently Amended) A method of preparing lymphocytes having dual specificity comprising:
contacting lymphocytes with a cell, ~~which cell~~ that is allogeneic to the lymphocytes;
and
transducing the lymphocytes with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen.
- 42.-43. (Cancelled)
44. (Previously Presented) The composition of claim 4, wherein the ovarian tumor antigen is folate binding protein (FBP).
45. (Previously Presented) The composition of claim 1, wherein the T lymphocyte is a human T lymphocyte.
46. (Previously Presented) The composition of claim 1, wherein the cell is a splenocyte, a dendritic cell, or a B cell.
47. (Previously Presented) The lymphocyte of claim 11, wherein the lymphocyte is a human lymphocyte.
48. (Previously Presented) The lymphocyte of claim 11, wherein the tumor antigen is an ovarian tumor antigen.
49. (Previously Presented) The lymphocyte of claim 48, wherein the ovarian tumor antigen is FBP.
50. (Previously Presented) The lymphocyte of claim 11, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, or a B cell.

51. (Previously Presented) The lymphocyte of claim 11, wherein the chimeric receptor is Mov- γ .
52. (Previously Presented) The pharmaceutical composition of claim 40, wherein the T lymphocyte is a human T lymphocyte.
53. (Previously Presented) The pharmaceutical composition of claim 40, wherein the chimeric receptor is Mov- γ .
54. (Previously Presented) The pharmaceutical composition of claim 40, wherein the tumor antigen is an ovarian tumor antigen.
55. (Previously Presented) The pharmaceutical composition of claim 53, wherein the ovarian tumor antigen is FBP.
56. (Previously Presented) The pharmaceutical composition of claim 40, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, a dendritic cell, or a B cell.
57. (Previously Presented) The method of claim 41, wherein the chimeric receptor is Mov- γ .
58. (Previously Presented) The method of claim 41, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, a dendritic cell, or a B cell.
59. (Previously Presented) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.
60. (Previously Presented) The method of claim 59, wherein the ovarian tumor antigen is FBP.
61. (Previously Presented) The method of claim 41, wherein the lymphocytes are human lymphocytes.
- 62.-70. (Cancelled)

71. (Previously Presented) The lymphocytes prepared by the method of claim 41.
72. (New) A composition comprising a T lymphocyte having (i) a recombinant T-cell receptor, which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte.
73. (New) The composition of claim 72, wherein the tumor antigen is an ovarian tumor antigen.
74. (New) The composition of claim 73, wherein the ovarian tumor antigen is folate binding protein (FBP).
75. (New) The composition of claim 72, wherein the cell is a peripheral blood mononuclear cell, splenocyte, a dendritic cell, or a B cell.
76. (New) The composition of claim 72, wherein the T lymphocyte is a human T lymphocyte.
77. (New) A composition comprising
(a) a T lymphocyte having
 (i) a recombinant chimeric receptor, which is reactive with a tumor antigen,
 and
 (ii) an endogenous T-cell receptor reactive with a cell that is allogeneic to the
 T lymphocyte, and
(b) the cell.
78. (New) A composition comprising
(a) a T lymphocyte having
 (i) a recombinant T-cell receptor, which is reactive with a tumor antigen, and
 (ii) an endogenous T-cell receptor reactive with a cell that is allogeneic to the
 T lymphocyte, and
(b) the cell.

79. (New) A composition comprising a population of T lymphocytes comprising
(a) a recombinant chimeric receptor that is reactive with a tumor antigen, and
(b) a T-cell receptor that is reactive with an allogeneic cell,
wherein the population of T-cells has been exposed to a cell that is allogeneic to at least one of the T lymphocytes of the population under conditions which expand and activate the T lymphocytes.
80. (New) A composition comprising a population of T lymphocytes of claim 79, wherein the population substantially consists of T-cells reactive with the allogeneic cell.
81. (New) A composition comprising a population of T lymphocytes comprising
(a) a recombinant T-cell receptor, which is reactive with a tumor antigen, and
(b) a T-cell receptor that is reactive with an allogeneic cell,
wherein the population of T-cells has been exposed to a cell that is allogeneic to at least one of the T lymphocytes of the population under conditions which expand and activate the T lymphocytes.
82. (New) A composition comprising a population of T lymphocytes of claim 81, wherein the population substantially consists of T-cells reactive with the allogeneic cell.